Janus Kinase 2

A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.

Also Known As:

Networked: 754 relevant articles (20 outcomes, 74 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Verstovsek, Srdan: 24 articles (05/2021 - 11/2005)
2.	Tefferi, Ayalew: 13 articles (01/2018 - 08/2005)
3.	Vainchenker, William: 9 articles (06/2021 - 06/2006)
4.	Vannucchi, Alessandro M: 9 articles (05/2021 - 08/2007)
5.	Constantinescu, Stefan N: 8 articles (06/2021 - 02/2009)
6.	Prchal, Josef T: 8 articles (12/2019 - 11/2005)
7.	Passamonti, Francesco: 7 articles (05/2021 - 11/2005)
8.	Kralovics, Robert: 7 articles (04/2020 - 11/2005)
9.	Mesa, Ruben: 7 articles (03/2020 - 08/2007)
10.	Funakoshi-Tago, Megumi: 7 articles (11/2019 - 05/2011)

Related Diseases

1.	Primary Myelofibrosis (Myelosclerosis) 06/01/2017 - "Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. " 03/01/2022 - "Bone marrow biopsy was consistent with pre-fibrotic myelofibrosis (Janus kinase 2 (JAK-2) positive). " 06/03/2019 - "Laboratory tests and bone marrow biopsy confirmed underlying systemic disease to be Janus kinase 2 mutation positive primary idiopathic myelofibrosis. " 12/01/2015 - "We report an extremely rare case of a female child who presented the onset of primary myelofibrosis (PMF) harboring JAK2 (Janus Kinase 2 gene) mutation (JAK2V617F) when she was 15 months old. " 01/01/2014 - "In 2005, the discovery of Janus kinase 2 (JAK2) V617F mutation in approximately half of patients with myelofibrosis (MF) marked an important milestone in our understanding of the pathophysiology of MF. "
2.	Neoplasms (Cancer) 02/01/2022 - "Prognostication of myeloproliferative neoplasm (MPN) has always been challenging, even with the advent of Janus kinase 2 (JAK2 V617F) molecular studies. " 10/06/2020 - "BACKGROUND Although the V617F mutation in the Janus kinase 2 (JAK2) gene and the breakpoint cluster region-abl1 (BCR-ABL1) oncogene fusion have been considered mutually exclusive in most myeloproliferative neoplasms (MPNs), many recent studies have described patients with both. " 12/01/2014 - "The aim of this study was to investigate the presence of Janus kinase 2 (JAK2) V617F mutation in patients with break point cluster region-abelson negative chronic myeloproliferative neoplasms (CMPNs) in our center. " 11/01/2012 - "This study evaluated potential correlations between the allele burden of the Janus kinase 2 (JAK2) V617F mutation and clinicohematologic characteristics in patients with myeloproliferative neoplasms (MPN). " 11/01/2010 - "Although clinical trials of the much anticipated small molecule inhibitors of Janus kinase 2 have shown that these experimental agents are successful in palliating many of the symptoms associated with the myeloproliferative neoplasms, they have not been reported to affect the disease initiating hematopoietic stem cell population or to alter the natural history of these disorders. "
3.	Reperfusion Injury 01/01/2019 - "Although inhibition of the Janus kinase 2 (JAK2)/STAT3 pathway has been reported to be protective against ischemia-reperfusion injury (IRI), the role of T cell-associated STAT3 in the pathogenesis of renal IRI has not been specifically defined. " 12/01/2019 - "Role of the Janus kinase 2/signal transducers and activators of transcription 3 pathway in the protective effect of remote ischemia preconditioning against cerebral ischemia-reperfusion injury in rats." 10/01/2017 - "Previous studies of our laboratory have demonstrated that activating Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway is involved in the protection against cerebral ischemia/reperfusion injury. " 01/01/2015 - "This study aims to investigate the effect of Cur on cerebral ischemia-reperfusion injury and whether the Janus kinase 2 and signal transducer and activator 3 of transcription (JAK2/STAT3) signaling pathway is involved in the neuroprotective effects of Cur. " 02/01/2019 - "To investigate the effect of sevoflurane on hepatic ischemia-reperfusion injury in rats via janus kinase 2/signal transducer and activator of transcription 3 (JAK2-STAT3) pathway. "
4.	Splenomegaly 05/01/2021 - "Janus kinase 2 (JAK2) inhibitors, the first targeted treatments for myeloproliferative neoplasms (MPNs), provide substantial benefits, including a marked reduction in splenomegaly and MPN-associated symptoms. " 01/01/2011 - "Although the administration of Janus Kinase 2 (JAK2) inhibitors to patients with PMF often dramatically reduces the degree of splenomegaly and improves in systemic symptoms, these drugs do not correct the cytopenias associated with PMF, nor do they reverse abnormalities of BM architecture or substantially influence the JAK2V617F allele burden. " 09/30/2009 - "In polycythemia vera (PV), an activating mutation in Janus kinase 2 (JAK2(V617)) induces splenomegaly and an increase in hematocrit. " 01/01/2022 - "Janus kinase 2 (JAK2) inhibitor Ruxolitinib is the first-line treatment for intermediate-II or high-risk MF patients with splenomegaly and constitutional symptoms, but most MF patients develop resistance or intolerance to Ruxolitinib. " 12/01/2017 - "The novel Janus kinase 2 (JAK2) inhibitor, ruxolitinib, has demonstrated marked improvements to constitutional symptoms and splenomegaly. "
5.	Ischemia 12/01/2010 - "Reply: Blockade of Janus kinase 2 signaling ameliorates mouse liver damage due to ischemia and reperfusion." 09/01/2010 - "Blockade of Janus kinase 2 signaling ameliorates mouse liver damage due to ischemia and reperfusion." 05/01/2011 - "Activation of the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) pathway is known to play a key role in cardiogenesis and to afford cardioprotection against ischemia-reperfusion in adult. " 12/01/2019 - "Role of the Janus kinase 2/signal transducers and activators of transcription 3 pathway in the protective effect of remote ischemia preconditioning against cerebral ischemia-reperfusion injury in rats." 03/01/2013 - "This review discusses the pathogenesis of thrombosis of mesenteric veins, the diagnosis and differentiation from arterial ischemia, the emergence of the JAK2 (Janus kinase 2) sequence variation as a marker of thrombophilia and myelodysplastic neoplasms, and new anticoagulants. "

Related Drugs and Biologics

1.	ruxolitinib
2.	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
3.	Proteins (Proteins, Gene)
4.	Janus Kinase 1
5.	Calreticulin
6.	Interleukin-6 (Interleukin 6)
7.	Hydroxyurea (Hydrea)
8.	Messenger RNA (mRNA)
9.	Member 1 Subfamily B ATP Binding Cassette Transporter
10.	CEP 33779

Related Therapies and Procedures

1.	Therapeutics
2.	Electroacupuncture
3.	Stem Cell Transplantation
4.	Punctures
5.	Ligation